Indication
For treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
Medicine details
- Medicine name:
- futibatinib (Lytgobi)
- SMC ID:
- SMC2661
- Pharmaceutical company
- Taiho Oncology
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Abbreviated
- Publication due date:
- TBC